| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Plg |
| Uniprot No | P00747 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-810aa |
| 氨基酸序列 | EPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFTCRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKNGITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILECEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRELRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWSAQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTEQLAPTAPPELTPVVQDCYHGDGQSYQGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAGLTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEEDCMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN |
| 预测分子量 | 92.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组纤溶酶原(Plasminogen, Plg)的参考文献摘要概括：
---
1. **文献名称**：*Recombinant human plasminogen production and purification: A novel approach for therapeutic applications*
**作者**：Smith J, et al.
**摘要**：研究报道了一种利用哺乳动物细胞表达系统高效生产重组人纤溶酶原(rhPlg)的方法，并通过亲和层析纯化获得高纯度蛋白。实验验证了其纤溶活性与天然Plg相当，为治疗遗传性Plg缺乏症提供了新策略。
---
2. **文献名称**：*Characterization of a novel recombinant plasminogen variant with enhanced fibrin binding capacity*
**作者**：Lee H, et al.
**摘要**：作者通过基因工程改造Plg的赖氨酸结合位点，成功表达了一种重组Plg变体(rPlg-K3)。该变体表现出更强的纤维蛋白结合能力，在体外血栓模型中溶解效率提升40%，为开发新型溶栓药物奠定基础。
---
3. **文献名称**：*Expression of functional plasminogen in Pichia pastoris: A cost-effective platform for large-scale production*
**作者**：Gómez-Romero M, et al.
**摘要**：研究利用毕赤酵母系统实现了重组Plg的高效表达，优化发酵条件后产量达1.2 g/L。纯化产物经功能验证显示完整酶原活性，为工业化生产Plg提供了经济可行的方案。
---
注：以上文献信息为示例性内容，实际文献需通过学术数据库检索获取。如需具体文章，建议使用关键词在PubMed或Google Scholar中查找。
**Background of Recombinant Plasminogen (Plg)**
Plasminogen (Plg), a glycoprotein synthesized primarily in the liver, is the inactive precursor of plasmin, a key enzyme in the fibrinolytic system. Circulating in blood and extracellular fluids, Plg plays a central role in degrading fibrin clots, tissue remodeling, and resolving inflammation. Its activation into plasmin is tightly regulated by activators (e.g., tissue-type plasminogen activator, tPA) and inhibitors (e.g., α2-antiplasmin), ensuring balanced fibrinolysis to prevent pathological bleeding or thrombosis.
Genetic deficiencies or dysregulation of Plg are linked to thrombotic disorders, impaired wound healing, and rare conditions like ligneous conjunctivitis. Traditional therapeutic approaches, such as plasma-derived Plg, face limitations in availability, safety, and standardization. Recombinant DNA technology offers a solution by enabling scalable production of recombinant human Plg (rhPlg) in controlled systems (e.g., mammalian cell cultures). This method ensures high purity, reduced infection risks, and consistent quality.
Research on rhPlg has expanded its potential beyond replacement therapy. Preclinical studies highlight its efficacy in enhancing clot lysis, accelerating tissue repair, and modulating inflammatory responses. In oncology, rhPlg is explored for its ability to degrade extracellular matrix components, potentially inhibiting metastasis. Additionally, engineered Plg variants with improved stability or targeted activation are under development to optimize therapeutic outcomes.
Clinical trials are evaluating rhPlg for hereditary Plg deficiency and as an adjunct in thrombolytic therapy. Its biocompatibility and multifunctional roles position rhPlg as a promising biologic, bridging gaps in treating fibrinolytic disorders and regenerative medicine. Continued innovation in production and bioengineering may further unlock its therapeutic versatility.
×
